All articles by  

  1. Merck to acquire Tilos Therapeutics for $773m

    Merck has signed an agreement to buy biopharmaceutical company Tilos Therapeutics for a total consideration of up to $773m. Founded…
    Read More…

    11 Jun
  2. Regulators demand more details on Roche’s $4.8bn Spark acquisition

    The US Federal Trade Commission (FTC) has requested that both Roche and Spark Therapeutics submit additional information and documentary material…
    Read More…

    11 Jun
  3. Genentech receives FDA approval for Polivy to treat DLBCL

    Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Polivy (polatuzumab vedotin-piiq)…
    Read More…

    11 Jun
  4. FDA advisory panel recommends TB Alliance’s tuberculosis drug

    An advisory panel to the US Food and Drug Administration (FDA) has recommended the approval of TB Alliance’s investigational drug…
    Read More…

    10 Jun
  5. Biogen closes $800m Nightstar Therapeutics acquisition

    Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market. Nightstar…
    Read More…

    10 Jun
  6. Janssen partners with nference for AI-based drug development

    Janssen Research & Development has collaborated with software solutions provider nference to leverage artificial intelligence (AI) and data sciences for…
    Read More…

    10 Jun
  7. Columbia University and Deerfield Management form drug R&D alliance

    Columbia University has formed a research and development (R&D) alliance with healthcare investment firm Deerfield Management to accelerate drug development….
    Read More…

    7 Jun
  8. Vertex to acquire Exonics Therapeutics for $245m

    Vertex Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of gene editing therapies developer Exonics Therapeutics for…
    Read More…

    7 Jun
  9. FDA grants fast-track designation to bone marrow cancer drug

    Sierra Oncology has received the US Food and Drug Administration’s (FDA) fast track designation for its investigational drug momelotinib. Indicated…
    Read More…

    7 Jun
  10. FDA agrees to review Celgene-Acceleron’s luspatercept in anaemia

    The US Food and Drug Administration (FDA) has accepted a biologics licence application (BLA) for Celgene and Acceleron Pharma’s luspatercept….
    Read More…

    6 Jun
Close
Close
Close

Go Top